Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 40-year-old man whose vitiligo and psoriasis responded favorably to ixekizumab after experiencing vitiligo onset and psoriasis relapse during adalimumab treatment.

This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement.

This report discusses two patients with plaque psoriasis who developed hypertrichosis, or excessive hair growth, while undergoing interleukin-17A inhibitor therapy.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

This systematic review reported an association between specific interleukin gene polymorphisms (IL-17A, IL-18, IL17RA, and IL16) and alopecia areata, suggesting further genetic studies are needed to confirm the interleukins' role in the disorder's progression.

TAK-279 effectively reduces psoriasis symptoms and is safe.

This study found that patients with alopecia areata and their healthy family members had elevated levels of Th1- and Th17-related cytokines, suggesting a genetic link in cytokine dysregulation.

This letter discusses a case of Hepatitis C-related vitiligo in a patient with Ivemark syndrome and presents no new clinical results.

This case report documents the first use of bimekizumab as monotherapy for dissecting cellulitis of the scalp, where a 27-year-old man experienced significant symptom relief without adverse effects after failing standard treatments.

This case report presents the first known instance of bimekizumab improving psoriatic scarring alopecia, suggesting potential benefits of dual IL-17A/IL-17F blockade for this rare and challenging condition, warranting further investigation.

This study found that Punica granatum ethanolic leaf extract may alleviate skin fibrosis in rats by modulating inflammation-related pathways and reducing dermal alterations.

In this case report, a 31-year-old male with refractory sycosis barbae achieved complete remission after 4 months of treatment with bimekizumab, suggesting this dual inhibitor of interleukin-17A and IL-17F may be a promising therapy for this condition.

This study found that patients with patchy alopecia areata had significantly higher serum levels of pro-inflammatory cytokines IL-6, TNF-α, IL-17A, and IL-21 compared to healthy controls, with these levels correlating positively with disease severity, age, and disease duration.

Minoxidil rejuvenates hair follicles and reduces aging signs in male pattern baldness.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

In this pilot study, minoxidil-treated scalp skin grafts from hair loss patients on mice showed increased expression of key anti-aging biomarkers and hair regrowth, suggesting minoxidil as a potential anti-aging agent by boosting VEGF-A production in hair follicles.

Hair follicles are crucial for maintaining skin barrier function.

In this case report, secukinumab therapy for spondyloarthritis was associated with the development of alopecia areata in a 46-year-old woman, which improved after discontinuing the medication.

In this study, researchers found that the protein eIF4E is crucial for keratinocyte proliferation in psoriasis, suggesting it as a potential treatment target for the condition.

This case control study investigated serum IL-17A levels in alopecia areata patients compared to healthy controls to explore its potential role in the disease's pathogenesis.

This study reported that an ex vivo organ culture system effectively induced aging-related changes in healthy human skin, allowing testing of senolytics like tretinoin, resveratrol, and caffeine.

This study found that sulfated CCK octapeptide reduces psoriasis-like skin inflammation in mice, suggesting a new pathophysiological role for CCK in regulating epidermal inflammation.

R-spondin2 may help treat hair loss, gene differences could explain baldness, a peptide's regulation is linked to psoriasis, B-defensin gene copies may affect a skin condition's risk and severity, and potential markers and targets for alopecia areata were identified.

Azathioprine may help with severe hair loss, a new topical treatment could counteract hair thinning, and trichoscopy can diagnose hair-pulling disorder effectively.

This study highlights the evolving understanding of acne's pathophysiology and suggests that targeting pro-inflammatory cytokines such as IL-1β, IL-17, IL-23, and TNFα with biological antibodies may offer new treatment strategies for severe acne and its scars.

This study found that chronic low-grade inflammation exists independently of excess weight or obesity in women with PCOS, with notable increases in specific cytokines such as IL-9, MCP-3, and MIP-1α.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

This study found that systemic treatment with DS77754007, a KLK5 inhibitor, improved skin symptoms in a mouse model of Netherton Syndrome more effectively than certain antibody treatments, suggesting KLK5 inhibition as a promising therapeutic approach for this condition.